Patient Voice

1 Trust Patient Insights at Both the Individual and National Level
   Paul T. Conway
   See related editorial and articles on pages 3, 63, 100 and 109.

Editorials

3 CJASN: What’s Behind and What’s Ahead
   Rajnish Mehrotra, Michel Chonchol, and Ian de Boer
   See related Patient Voice editorial on page 1.

4 New Frontiers in Treating Uremic Metabolic Acidosis
   Denver Brown and Michal L. Melamed
   See related article on page 26.

6 Lowering Expectations with Niacin Treatment for CKD-MBD
   Tilman B. Dru¨eke and Ziad A. Massy
   See related article on page 36.

9 Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction: Balancing Risks and Benefits of BP Reduction in Hypertension
   Hala Yamout and George L. Bakris
   See related article on page 73.

11 Life Expectancy Gains for Patients with ESRD
   Kirsten L. Johansen
   See related article on page 91.

13 Compelling Evidence of the Need for Policy Change to Decrease Deceased Donor Kidney Discard in the United States: Waste Not Want Less
   Matthew Kadatz and John S. Gill
   See related article on page 118.

Original Articles

Acute Kidney Injury and ICU Nephrology

16 Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT
   Andrew S. Allegretti, Xavier Vela Parada, Nwamaka D. Eneanya, Hannah Gilligan, Dihua Xu, Sophia Zhao, Jules L. Dienstag, Raymond T. Chung, and Ravi I. Thadhani

Chronic Kidney Disease

26 Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD
   David A. Bushinsky, Thomas Hostetter, Gerrit Klaerner, Yuri Stasiv, Claire Lockey, Sarah McNulty, Angela Lee, Dawn Parsell, Vandana Mathur, Elizabeth Li, Jerry Buysse, and Robert Alpern
   See related editorial on page 4.
Chronic Kidney Disease (Continued)

36 The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD
Rakesh Malhotra, Ronit Katz, Andrew Hooinagle, Andrew Bostom, Dena E. Rifkin, Ruth Mcbride, Jeffrey Probstfield, Geoffrey Block, and Joachim H. Ix
See related editorial on page 6.

45 FGF23 and Left Ventricular Hypertrophy in Children with CKD
Mark M. Mitsnefes, Aisha Betoko, Michael F. Schneider, Isidro B. Salusky, Myles Selig Wolf, Harald Jüppner, Bradley A. Warady, Susan L. Furth, and Anthony A. Portale

Genetics

53 Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome

Glomerular and Tubulointerstitial Diseases

63 Predicting Outcome in Patients with Anti-GBM Glomerulonephritis
See related Patient Voice editorial on page 1.

Hypertension

73 BP Reduction, Kidney Function Decline, and Cardiovascular Events in Patients without CKD
Rita Magriço, Miguel Bigotte Vieira, Catarina Viegas Dias, Lia Leitão, and João Sérgio Neves
See related editorial on page 9.

Maintenance Dialysis

81 Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD
Michel Fischbach, Elke Wühl, Sylvie C. Meyer Reigner, Zoe Morgan, and Franz Schaefer

91 Changes in Excess Mortality from End Stage Renal Disease in the United States from 1995 to 2013
Bethany J. Foster, Mark M. Mitsnefes, Mourad Dahhou, Xun Zhang, and Benjamin L. Laskin
See related editorial on page 11.

100 A Discrete Choice Study of Patient Preferences for Dialysis Modalities
See related Patient Voice editorial on page 1.

Transplantation

109 Re-Establishing Brain Networks in Patients with ESRD after Successful Kidney Transplantation
Hui Juan Chen, Jiqiu Wen, Rongfeng Qi, Jianhui Zhong, U. Joseph Schoepf, Akos Varga-Szemes, Virginia W. Lesslie, Xiang Kong, Yun Fei Wang, Qiang Xu, Zhe Zhang, Xue Li, Guang Ming Lu, and Long Jiang Zhang
See related Patient Voice editorial on page 1.

118 Characteristics and Performance of Unilateral Kidney Transplants from Deceased Donors
See related editorial on page 13.
A 41-year-old Caucasian man with long-standing HIV was recently evaluated for elevated serum creatinine. He has been exposed to multiple combined anti-retroviral therapy (cART) agents, some of which are known to cause kidney injury, including tenofovir. He has also been on cART known to cause elevations in serum creatinine, including cobicistat. A recent ECG showed evidence of left ventricular hypertrophy. A follow-up echocardiogram re-demonstrated LVH, with MRI findings suggestive of Fabry Disease. Leukocyte alpha galactosidase level was measured at 0 (normal ≥ 23.1 nmol/hour/mg protein). He was started on agalsidase beta infusions every 2 weeks. The patient’s serum creatinine was 1.7 mg/dL in January of 2017; to evaluate any potential kidney involvement, he was referred to Nephrology. A percutaneous kidney biopsy was performed, showing characteristic foamy, lipid-laden cells in glomeruli, tubules, and interstitium. Light microscopy (H&E) shows a glomerulus with large foamy-appearing podocytes (arrows). Electron Microscopy shows renal tubular epithelium with classic lipid inclusion bodies characteristic of Fabry Disease.
Fabry Disease is an X-linked lysosomal storage disorder caused by a mutation in the GLA gene, leading to a deficiency in the enzyme alpha-galactosidase A. This can lead to damage in multiple organs including the heart, brain, and kidney due to cellular glycosphingolipid accumulation. Diagnosis is made based on serum testing in men and genetic analysis in women. In patients with multiple potential causes for renal dysfunction, which in this gentleman includes HIV and HIV-related medications, in addition to Fabry disease, it is essential to perform kidney biopsy. (Images and text provided by Steven Menez, Lois Arend and Mohamed Atta from Johns Hopkins School of Medicine, Baltimore, Maryland)

References: